Since the 2018 guideline’s publication, additional non-statin therapies such as bempedoic acid, evinacumab, and inclisiran, have been approved by the FDA for the management of hypercholesterolemia.
Mickenzie Meyers, PharmD Candidate
Advertisement
Articles by Mickenzie Meyers, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Current and Emerging BCMAxCD3 Bispecifics
3
Same Pathway, Different Profiles: Clinical Considerations for Alpelisib, Capivasertib, and Inavolisib
4
Evolocumab Reduces Risk of Major Events in Patients Without Prior Cardiovascular History
5
